Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Non-Current Assets (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Other Non-Current Assets for 7 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 11.11% to $1.0 million in Q4 2025 year-over-year; TTM through Nov 2025 was $1.0 million, a 11.11% increase, with the full-year FY2025 number at $1.0 million, up 11.11% from a year prior.
  • Other Non-Current Assets was $1.0 million for Q4 2025 at Nurix Therapeutics, down from $7.4 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $7.4 million in Q3 2025 to a low of $170000.0 in Q1 2021.
  • A 5-year average of $1.2 million and a median of $901000.0 in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: plummeted 67.18% in 2022, then skyrocketed 718.53% in 2025.
  • Nurix Therapeutics' Other Non-Current Assets stood at $300000.0 in 2021, then soared by 200.33% to $901000.0 in 2022, then changed by 0.0% to $901000.0 in 2023, then dropped by 0.11% to $900000.0 in 2024, then rose by 11.11% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Other Non-Current Assets are $1.0 million (Q4 2025), $7.4 million (Q3 2025), and $901000.0 (Q2 2025).